JAK inhibitors in COVID-19: the need for vigilance regarding increased inherent thrombotic risk

Puja Mehta, Coziana Ciurtin, Marie Scully, Marcel Levi, Rachel C. Chambers

Source: Eur Respir J, 56 (3) 2001919; 10.1183/13993003.01919-2020
Journal Issue: September
Disease area: Pulmonary vascular diseases, Respiratory critical care

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Puja Mehta, Coziana Ciurtin, Marie Scully, Marcel Levi, Rachel C. Chambers. JAK inhibitors in COVID-19: the need for vigilance regarding increased inherent thrombotic risk. Eur Respir J, 56 (3) 2001919; 10.1183/13993003.01919-2020

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: